Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Jul 20, 2016 2:23pm
63 Views
Post# 25069558

RE:RE:RE:RE:RE:RE:RE:RE:Scarpa's extraordinary data?

RE:RE:RE:RE:RE:RE:RE:RE:Scarpa's extraordinary data?
JD:
You had no idea that the company was toast.
Somebody else posted that the company was bankrupt.
So don't go peddling that around. That wasn't the case you were making.

Jekyl Jr:
False! Did you even read the original post?

Getting out my Dlck Tracy Tookit, I see it now. Expecting the reader to go to that last link to find information you didn't even mention in your post is rather bogus.

Being kind, perhaps you were trying to point to a company that was in the BBB business but they failed therefore BTI will fail?  If so, no where in that post did you make that point.  

You, so far today...

You're suggesting that because another BBB company failed, therefore BTI will as well.

BTI stock price hasn't moved on preclinical data, therefore they have nothing.

None of that makes any sense of course. You really need to work on your critical thinking skills.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities